iOx Therapeutics (iOx) is a near clinical stage biotechnology company developing a series of synthetic lipid compounds to prime and boost an immune response in cancer patients by stimulating invariant natural killer T cells (iNKT). The Company’s two lead compounds, IMM60 and IMM65, are expected to enter the clinic in the next year.
Portage owns approximately 60% of iOx. Portage serves as Chief Executive Officer, Chief Scientific Officer, and provides project management and financial roles. In addition, Portage holds the Chairman and executive member seats on the Board of Directors.